Allogene Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 98.7 million compared to USD 79.85 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.56 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.47 USD | +0.29% | -2.25% | +8.10% |
Mar. 18 | Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index | CI |
Mar. 15 | Allogene Therapeutics Files $500 Million Mixed Shelf | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.10% | 585M | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023